Home/ Stocks/ CTMX

CytomX Therapeutics, Inc.

CTMX XNAS

$3.98 -0.02 (-0.50%) ▼ 15-min delayed

Open

$4.04

High

$4.23

Low

$3.85

Volume

5.06M

Market Cap

$866.46M

About CytomX Therapeutics, Inc.

CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.

Sector: PHARMACEUTICAL PREPARATIONS Employees: 69 Website →

Key Financials

Period	Revenue	Net Income	EPS
Q1 2026	$10.26M	$-18,248,000	N/A
FY 2025	$76.20M	$-17,368,000	N/A
Q3 2025	$5.96M	$-14,229,000	N/A
Q2 2025	$18.66M	$-154,000	N/A

Earnings & Analyst Ratings

Next Earnings: Wed, Aug 5, 2026

Calendar →

Related Market News

No specific coverage for CTMX yet. Check out our latest market news or earnings calendar.

Get CTMX Alerts

Stay ahead with breaking news, price alerts, and expert analysis on CytomX Therapeutics, Inc..

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.